CereVasc is a clinical-stage medical device company focused on developing novel, minimally invasive treatments for patients with neurological diseases. Its initial product, the eShunt System, employs an innovative percutaneous transvenous-transdural approach to the central nervous system and is intended to enable the first minimally invasive treatment for communicating hydrocephalus (CH). The patented eShunt System includes an endovascularly implantable cerebrospinal fluid shunt and delivery components designed to treat CH without invasive surgery.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
06/04/26	$85,000,000	Series C	Bain Capital Life Sciences Johnson & Johnson Innovation Medtronic Perceptive Xontogeny Ventures Piper Sandler Merchant Banking	undisclosed